MX2018010958A - Vacuna para virus de zika atenuado vivo. - Google Patents

Vacuna para virus de zika atenuado vivo.

Info

Publication number
MX2018010958A
MX2018010958A MX2018010958A MX2018010958A MX2018010958A MX 2018010958 A MX2018010958 A MX 2018010958A MX 2018010958 A MX2018010958 A MX 2018010958A MX 2018010958 A MX2018010958 A MX 2018010958A MX 2018010958 A MX2018010958 A MX 2018010958A
Authority
MX
Mexico
Prior art keywords
virus
attenuated
zikv
vaccines
zika
Prior art date
Application number
MX2018010958A
Other languages
English (en)
Inventor
S Whitehead Stephen
E Woodson Sara
P Durbin Anna
G Pletnev Alexander
A Tsetsarkin Konstantin
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2018010958A publication Critical patent/MX2018010958A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción se relaciona a virus de Zika atenuados y vacunas, virus de Zika quiméricos atenuados y vacunas, y a composiciones inmunogénicas multivalentes que comprenden vacunas para Zika y vacunas para otros flavivirus. El virus de Zika quimérico incluye una primera secuencia de nucleótidos que codifica por lo menos una proteína estructural de un virus de Zika (ZIKV), una segunda secuencia de nucleótidos que codifica por lo menos una proteína no estructural de un primer flavivirus, y una tercera secuencia de nucleótidos de una región (3´) no traducida de un segundo flavivirus. Las composiciones inmunogénicas multivalentes comprenden una vacuna para ZIKV atenuado o una vacuna para ZIKV quimérico atenuado (o su combinación) junto con uno o más de un primer virus atenuado que es inmunogénico contra el serotipo (1) de dengue, un segundo virus atenuado que es inmunogénico contra el serotipo (2) de dengue, un tercer virus atenuado que es inmunogénico contra el serotipo (3) de dengue, y un cuarto virus atenuado que es inmunogénico contra el serotipo (4) de dengue. La presente descripción además se relaciona a métodos para inducir respuestas inmunes, así como prevenir o tratar infecciones de ZIKV, y en ciertas modalidades, la prevención combinada o tratamiento de ZIKV y otro flavivirus, por ejemplo, virus de dengue.
MX2018010958A 2016-03-11 2017-03-11 Vacuna para virus de zika atenuado vivo. MX2018010958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307170P 2016-03-11 2016-03-11
PCT/US2017/021989 WO2017156511A1 (en) 2016-03-11 2017-03-11 Live attenuated zika virus vaccine

Publications (1)

Publication Number Publication Date
MX2018010958A true MX2018010958A (es) 2019-02-07

Family

ID=58428363

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010958A MX2018010958A (es) 2016-03-11 2017-03-11 Vacuna para virus de zika atenuado vivo.

Country Status (11)

Country Link
US (1) US20190194260A1 (es)
EP (1) EP3426292A1 (es)
JP (1) JP2019511221A (es)
KR (1) KR20180127397A (es)
CN (1) CN109152828A (es)
AU (1) AU2017230112A1 (es)
BR (1) BR112018068342A2 (es)
CA (1) CA3016697A1 (es)
CO (1) CO2018010874A2 (es)
MX (1) MX2018010958A (es)
WO (1) WO2017156511A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
GB201716307D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Chimeric yellow fever zika virus strain
EP3710046A4 (en) 2017-11-10 2021-11-17 The Research Institute at Nationwide Children's Hospital RECOMBINANT VECTORS CODING FOR ZIKA VIRUS PROTEIN SUB-UNITS
WO2020051080A1 (en) * 2018-09-04 2020-03-12 The Board Of Regents Of The University Of Texas System Dna plasmid-launched live-attenuated vaccines for plus-sense single stranded rna viruses
MX2022000038A (es) * 2019-06-25 2022-02-24 Codagenix Inc Virus del dengue atenuados.
EP4277641A1 (en) * 2021-02-26 2023-11-22 Duke University Compositions for and methods of improving gene therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1978027B1 (en) 2000-02-10 2012-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Full-length infectious cDNA clones of tick borne flavivirus
CA3060687C (en) 2001-05-22 2021-05-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
CA2472468C (en) 2002-01-10 2015-11-24 Alexander G. Pletnev Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
WO2003092592A2 (en) 2002-05-03 2003-11-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
CA2548808C (en) 2003-12-08 2015-07-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
WO2006036233A1 (en) 2004-06-14 2006-04-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services West nile viruses with mutations in the 3’ terminal stem and loop secondary structure for use as live virus vaccines
AU2007285929B2 (en) 2006-08-15 2013-09-05 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
WO2008157136A1 (en) 2007-06-14 2008-12-24 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Chimeric sle/dengue type 4 antigenic viruses
WO2012065105A2 (en) * 2010-11-12 2012-05-18 Thomas Monath Chimeric flavivirus vaccines

Also Published As

Publication number Publication date
US20190194260A1 (en) 2019-06-27
CA3016697A1 (en) 2017-09-14
KR20180127397A (ko) 2018-11-28
CN109152828A (zh) 2019-01-04
CO2018010874A2 (es) 2018-10-22
WO2017156511A8 (en) 2018-09-27
WO2017156511A1 (en) 2017-09-14
AU2017230112A1 (en) 2018-10-04
JP2019511221A (ja) 2019-04-25
EP3426292A1 (en) 2019-01-16
BR112018068342A2 (pt) 2019-01-15

Similar Documents

Publication Publication Date Title
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
EA201800108A1 (ru) Вакцинные композиции для профилактики абровирусных инфекций
MX2018014573A (es) Vacuna contra el virus del zika.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
EA201892735A1 (ru) Состав вакцины против hiv
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
ECSP18026090A (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
PH12015000376A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CL2022002412A1 (es) Vacuna
PH12015502666B1 (en) Dengue virus vaccine compositions and methods of use thereof
BR112017028212A2 (pt) vacinação concomitante contra dengue e febre amarela
GEP20237539B (en) Formulations of dengue virus vaccine compositions
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
NZ631012A (en) Compositions and methods for live, attenuated alphavirus formulations
CR20170280A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
PH12018501107A1 (en) Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens
AR101932A1 (es) Agente con propiedades antivirales para prevenir o tratar peces expuestos a un virus de la familia birnaviridae
WO2019113285A3 (en) Zika vaccines and methods of use